Welcome to Insider Trades Daily, glad you're here! Every day, more than 500,000 investors use this newsletter to track insider buying and selling across major public companies. It’s a simple way to see what the people closest to the business are doing with their own money. Before we start sending your daily updates, there’s just one quick thing left to do. Please confirm your subscription using the link below. Click Here to Confirm Your Subscription to Insider Trades Daily It takes a few seconds and helps make sure your newsletter shows up where it belongs, your inbox, not a spam folder. Once you’re confirmed, we’ll take it from there and deliver clear, no-nonsense insider trading insights straight to you. Start Receiving Insider Information The InsiderTrades.com Team P.S. If there's anything we can do to improve your experience, please let us know by replying to this email.
Further Reading from MarketBeat Media
Hims & Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery?Reported by Jessica Mitacek. Posted: 5/12/2026. 
Key Points
- Hims & Hers shares plunged over 12% in after-hours trading after reporting a Q1 double-miss, with an EPS loss of negative 40 cents versus four cents expected and year-over-year revenue growth of just 3.8%.
- The company is seeing success with its Novo Nordisk partnership, fulfilling over 125,000 Wegovy shipments in Q1, and planning to bolster its global footprint through the acquisition of Eucalyptus.
- Management raised full-year guidance and reiterated ambitious 2030 revenue targets, supported by operating in high-growth telehealth and weight-loss markets that are projected to expand significantly through the end of the decade.
- Special Report: Elon Musk: This Could Turn $100 into $100,000
Shares of telehealth provider Hims & Hers Health (NYSE: HIMS) sold off sharply after disappointing Q1 FY2026 financial results. The stock fell more than 12% in after-hours trading on May 11, following the company’s report. Expectations for the quarter were high, particularly after the company partnered with Danish multinational pharmaceutical firm Novo Nordisk (NYSE: NVO).
After 40 years in the markets, Dr. David Eifrig, MD, MBA, CEO of MarketWise, says what he sees right now genuinely worries him - and it has nothing to do with his own portfolio.
Nearly half the U.S. population has retirement savings concentrated in what he calls the most dangerous corner of the market, without realizing it. His team has identified a signal that may pinpoint the exact day this bull market turns.
He has outlined 3 steps to help you reposition before the shift happens. Watch Dr. Eifrig's urgent presentation and learn the 3 steps now
In March, Novo Nordisk dismissed its patent infringement lawsuit against Hims & Hers Health and entered into a partnership with the company to sell its GLP-1 weight loss drugs Wegovy and Ozempic on the telehealth platform. But that wasn’t enough to keep the company from posting a double miss in its Q1 report. The result marked the company’s fourth miss on both earnings and revenue in the past five quarters. Shares of HIMS are now down more than 50% over the past year, including a loss of nearly 20% year-to-date. The Losing Streak Continues for Hims & Hers HealthOn Monday, the company reported a Q1 earnings per share (EPS) loss of 40 cents, missing analyst expectations by a wide margin. Quarterly revenue came in at $608.10 million, also below the consensus estimate of $616.84 million. Concerningly, that figure represents just 3.8% year-over-year revenue growth. The company attributed the slower revenue growth and earnings loss to approximately $33 million in restructuring charges, including a roughly $28 million write-down tied to the GLP-1 compounding pivot. The earnings report wasn’t all bad news, though. Hims & Hers Health highlighted how its GLP-1 strategy pivot with Novo Nordisk is already bearing fruit. The company fulfilled more than 125,000 Wegovy shipments in Q1 and is on track to add more than 100,000 new weight-loss subscribers per month. Hims & Hers also noted that international expansion is increasingly a strategic focus. The acquisition of Eucalyptus is expected to be completed in the second half of the year, broadening the company’s global footprint and supporting its 2030 targets of at least $6.5 billion in annual revenue and $1.3 billion in adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA). In his earnings call comments, CEO Andrew Dudum said the company’s growing international reach is becoming a competitive advantage because it expands its total addressable market, increases its value to industry partners, and strengthens platform network effects. Perhaps most importantly for buy-and-hold investors, management raised its full-year guidance for revenue to a range of $2.8 billion to $3 billion and adjusted EBITDA to $275 million to $350 million. Dudum added that “2026 is proving to be a year of accelerating growth, which reinforces our confidence in our ambitious 2030 targets.” Hims & Hers Remains a Growth StoryThe company sits at the intersection of multiple high-growth markets. According to industry consultancy firm Grand View Research, the global weight loss supplement market, which was valued at $33.14 billion in 2024, is expected to post a compound annual growth rate (CAGR) of 14.17% from 2025 to 2030, reaching nearly $72 billion. Grand View Research forecasts that the global telehealth market will experience even faster growth, with a CAGR of 24.68% from 2025 to 2030. That would lift its value from just over $123 billion in 2024 to more than $455 billion by the end of the forecast period. And while growth for the global hair thinning market is not expected to be as strong as in telehealth and weight loss, Grand View Research projects a CAGR of 10.85% from 2025 to 2030. Those markets’ projected growth bodes well for Hims & Hers Health, which is in the process of transitioning from a niche wellness brand into a comprehensive, technology-driven healthcare platform. The company is also expanding into cardiovascular screenings, preventive care, dermatology, and diagnostic partnerships. The Long-Term Prospects Remain PositiveDespite the recent selloff, analyst expectations remain mostly positive. While the stock carries a consensus Hold rating, its average 12-month price target suggests more than 15% potential upside. The high-end price target of $60 implies as much as 100% upside, while the low-end target of $18 suggests shares of HIMS could face additional losses of around 38%. In the short term, traders should expect more volatility ahead. Current short interest is concerningly high at more than 31%. And while institutional activity slowed dramatically in Q1, sellers outnumbered buyers in Q4 FY2025, with outflows of $861 million easily surpassing inflows of $318 million. At the same time, the stock has seen insider buying disappear, while insider selling has totaled nearly $125 million over the past year. That has pushed insider ownership down to less than 13%. With a trailing 12-month EPS of 51 cents and a forward price-to-earnings ratio of around 48, Hims & Hers Health’s earnings are expected to grow more than 26% over the next year, from 53 cents per share to 67 cents per share. |
Post a Comment
Post a Comment